American Conference Institute’s 9th Annual Paragraph IV Disputes

American Conference Institute’s 9th Annual Paragraph IV Disputes

Speaking Engagement
It is estimated that the industry will experience patent losses approaching $150 billion within the next three years. This will undoubtedly test the balance of power created by the Hatch-Waxman Act and lead to dramatic new litigation challenges for brand names and generics.

Now in its ninth iteration, American Conference Institute's (ACI's) Paragraph IV Disputes conference is the only event which helps both brand name and generic pharmaceutical companies make sense of changing industry dynamics precipitated by the patent cliff and other factors such as patent reform, regulatory shifts and recent and pending case law. This is the conference that not only sets the standards for Paragraph IV litigation, but also serves as the annual meeting place for the “who's who” of pharmaceutical patent litigation.

WilmerHale Partner Robert Gunther will speak on the panel “Exploring Possible New Grounds Paragraph IV Invalidity Challenges: How 101 Rejections Under Myriad and Findings of 112 Indefiniteness Under Nautilus May Alter Paragraph IV Litigation.”

Read More About the Event



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.